A plain-spoken reading room for the semaglutide literature — the oral tablet and the once-weekly shot, side by side, from STEP 1 and SUSTAIN-6 to SELECT, FLOW and SURMOUNT-5.
Pharmacy Semaglutide

Oral Semaglutide: What the Research Shows vs the Injection

The short version

Oral semaglutide is the pill version of the same GLP-1 medicine that's better known as a once-weekly shot. Swallowing a peptide is genuinely hard — your stomach digests proteins for a living — so the tablet is built with a helper ingredient called SNAC that lets a small slice of the dose slip into your bloodstream intact. Even so, only about 0.4-1% of an oral dose is absorbed, which is why the pill has to be taken on an empty stomach with just a small sip of water, and why oral doses are much higher in milligrams than the injection [8].

Does the pill work? Yes. In diabetes trials it lowered blood sugar and weight, and at higher research doses (50 mg daily) it produced meaningful weight loss [9][11]. The honest trade-off: the tablet demands strict timing to work, while the once-weekly injection is absorbed far more reliably. Below we put the two routes side by side. No dosing instructions here — just what the studies documented.

How the tablet gets absorbed: the SNAC story

The tablet's secret ingredient is SNAC — sodium N-(8-[2-hydroxybenzoyl]amino)caprylate. It's an absorption enhancer co-formulated with oral semaglutide. SNAC briefly raises the local pH right around the tablet in the stomach and helps the peptide stay in its absorbable single-molecule form, so a small amount can cross the stomach lining before it's destroyed [8].

It's a clever fix, but a fragile one. Oral bioavailability lands at only about 0.4-1%, so the absorbed dose is exquisitely sensitive to how the tablet is taken. The label-documented requirement is to take it on an empty stomach, separated from food, drink, and other oral medicines, with no more than a small amount of water. We present that as a documented pharmacology fact about the formulation — not as instructions to any reader. The point for this site is structural: the injection skips this entire problem by going straight under the skin, where absorption is around 89%.

Semaglutide injection: the other route

The semaglutide injection is the once-weekly subcutaneous form — the one behind STEP 1, SUSTAIN-6, SELECT, and FLOW. Given under the skin, it's absorbed efficiently (roughly 89% bioavailability) and dosed once a week, which is why the big outcome trials used it [1][2][3][6].

In the trials, the weekly injection was titrated upward over weeks to ease the stomach into it, with weight-management dosing reaching 2.4 mg once weekly and diabetes dosing commonly maintained at 0.5-1.0 mg weekly [1][2]. Those are trial-documented and label-documented schedules described here in the third person, never as a recommendation. The practical contrast with the tablet is simple: the injection trades a needle for reliable absorption and a once-a-week rhythm, while the tablet trades reliability and strict timing for no needle.

Oral vs injection: a side-by-side read

Here's the comparison laid out plainly. Both forms are the same molecule, semaglutide, and both are FDA-approved; they differ in how they get in and how often you take them.

| Feature | Oral tablet | Once-weekly injection | |---|---|---| | Route | Swallowed | Under the skin (subcutaneous) | | Frequency | Once daily | Once weekly | | Absorption (bioavailability) | ~0.4-1%, SNAC-enabled [8] | ~89% | | Administration | Empty stomach, small sip of water, separated from food and other meds [8] | Self-injected; no fasting requirement | | Trial families | PIONEER (diabetes), OASIS (weight) [9][11] | STEP, SUSTAIN, SELECT, FLOW [1][2][3][6] | | Half-life | ~1 week | ~1 week |

The headline takeaway: the tablet wins on convenience (no needle) but is far more demanding to take correctly, because so little is absorbed [8]. The injection wins on reliable absorption and a simple weekly cadence. Both routes have produced real weight and metabolic results in trials — they're two doors into the same room. The shared ~1-week half-life is covered on the semaglutide half life page.

Oral doses studied in the trials

The oral program studied a different milligram range than the injection, precisely because so little is absorbed. PIONEER 1 established once-daily oral semaglutide at 3, 7, and 14 mg in type 2 diabetes, with dose-dependent drops in HbA1c and body weight versus placebo [11]. PIONEER PLUS then pushed higher — 25 mg and 50 mg once daily — and showed greater glycemic and weight improvements than the 14 mg dose in diabetes inadequately controlled on prior therapy [10]. For weight specifically, the OASIS program tested 50 mg once daily and found clinically meaningful weight loss versus placebo in adults with overweight or obesity without diabetes [9].

All of these are doses administered in published trials, reported here in the third person. None of it is dosing guidance, and the strict empty-stomach requirement that governs whether any of it is actually absorbed is a documented property of the SNAC formulation [8].